医学临床研究
   Apr. 6, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (10): 1560-1562    DOI: 10.3969/j.issn.1671-7171.2022.10.033
Original Articles Current Issue | Archive | Adv Search |
Clinical Efficacy of Ganciclovir in the Treatment of Cytomegalovirus Hepatitis in Children
GUO Hui-min, ZHANG Yan-xiang, SONG Jian-gang
Department of Pediatrics Baota District People's Hospital,Yan'an Shaanxi 716000
Download: PDF (1102 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To investigate the clinical efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) hepatitis in children. 【Methods】 The clinical data of 88 children with cytomegalovirus hepatitis admitted to our hospital from March 2019 to March 2021 were analyzed retrospectively. They were divided into observation group and control group according to different antiviral drugs, with 44 cases in each group. The children in the control group were treated with reduced glutathione, and the children in the observation group were treated with ganciclovir on the basis of the control group. The jaundice regression time, liver retraction time, spleen retraction time, the level serum total bilirubin (TBIL), alanine aminotransferase (ALT), γ- glutamyltranspeptidase (GGT) before and after the therapy and the clinical efficacy and adverse reactions of the two groups were compared.【Results】 The time of jaundice regression, liver retraction and spleen retraction in the observation group was significantly lower than that in the control group (P<0.05). After treatment, the levels of serum TBIL, ALT and GGT in the two groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). The total clinical effective rate in the observation group was 93.18% (41/44), higher than that in the control group [77.27% (34/44)], with a statistically significant difference(χ2=4.423,P=0.036). There was no significant difference in the incidence of adverse reactions between the two groups(χ2=1.048,P=0.310).【Conclusion】 Ganciclovir antiviral therapy can shorten the time of clinical symptom disappearance, promote the recovery of liver function, and it is safe and reliable.
Key wordsHepatitis, Viral, Human/ DT      Cytomegalovirus Infections      Ganciclovir/PD      Treatment Outcome     
Received: 26 August 2022     
PACS:  R725.126  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
GUO Hui-min
ZHANG Yan-xiang
SONG Jian-gang
Cite this article:   
GUO Hui-min,ZHANG Yan-xiang,SONG Jian-gang. Clinical Efficacy of Ganciclovir in the Treatment of Cytomegalovirus Hepatitis in Children[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1560-1562.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.10.033     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I10/1560
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech